RVBA-GSKPharma Manufacturing

GSK — in detail

Full extracted data, every event in the company's history we've captured, and (soon) external news. The full ratios diagnostic with peer benchmarks lives at /ratios.

Reference sources (3/5)

Source documents
Recent disclosure
Multi-year metrics
Targets
Certifications

External news· 1 ESG-tagged · GDELT

tagged categories: climate · governance · controversy · M&A · regulatory

Source: GDELT 2.0 DOC API · ESG-keyword filtered · 3-month trailing window.

Data by year· every metric + key events per year

Each year shows the firm's reported metrics on the left and the most material events on the right. Up to 10 events per year; the full event log is one click further.

2025

annual report ↗

Climate · carbon footprint (tCO2e)

Scope 1	479,000
Scope 2 (market-based)	7,000
Gross carbon footprint	—
Net carbon footprint	—

Energy (kWh)

Total energy	2.5B
Renewable electricity %	99%

Nature

waste generated t	39,000tonnes
deforestation risk assessed pctⓘ	51%
water withdrawal m3	6.8Mm3

Social

workforce female pct	49%
workforce management female pct	51%
workforce board female pct	50%
supply chain audited pctⓘ	92%

Governance

esg linked executive pay yn	1
internal carbon price usd per tco2eⓘ	70GBP per tCO2e
board independence pct	75%
audit assurance climate levelⓘ	1

P&L highlights (USD)

Headcount (FTE)	66,841people
Revenue	32.7B
Cost of revenue	(9B)
Gross profit	23.7B
Operating expenses (S&M + G&A)	(15.3B)
Operating income	8.3B
Net income	5.7B

Balance sheet highlights (USD)

Property, plant & equipment	9.3B
Right-of-use (leased) assets	726M
Total assets	61.1B
Total debt	17.7B
Cash & equivalents	3.4B
Minority interest	-421M

Market & shares

Market cap (FY-end)	74.4B
Shares outstanding	1B

Events 2025· 33

Acquisition of BP Asset IX, Inc. (efimosfermin)

GSK completed the acquisition of BP Asset IX, Inc., a subsidiary of Boston Pharmaceuticals, providing access to efimosfermin alfa, a phase III-ready investigational medicine for steatotic liver disease.

▾ expand

Dependent: Product and packaging eco-design (25% environmental impact reduction target)

GSK has finalised scope and methodology for its target of a 25% environmental impact reduction for products and packaging by 2030, focused on products anticipated to be the main drivers of its 2030 carbon footprint. As of 2025, 42% of in-scope products (including anti-infectives and respiratory portfolios) have environmental impact reduction plans in place, with all in-scope products targeted to have plans by end-2026.

▾ expand

Primary: Sales fleet electrification

As part of its Scope 1 direct-operations decarbonisation pathway to 2030, GSK is increasing the use of electric vehicles within its sales fleet, while acknowledging risks from vehicle availability, charging infrastructure and battery production constraints that could restrict full transition to 100% EVs by 2030.

▾ expand

Primary: Low-carbon Ventolin (MDI propellant reformulation)

GSK's reliever inhaler Ventolin accounts for ~43% of its total carbon footprint due to the high global-warming-potential HFA134a propellant. GSK has developed a next-generation Ventolin MDI using the low-carbon propellant HFA-152a, with positive pivotal phase III data confirming a 92% reduction in per-inhaler carbon footprint; regulatory submissions are underway with launch expected from 2026.

▾ expand

Achieved 2025 target of 100% renewable imported electricity

GSK achieved its 2025 target to transition 100% of imported electricity to renewable sources, ahead of its broader 2030 target of 100% renewably imported and generated electricity (currently at 85%).

▾ expand

Restated 2024 disciplinary/inspection data for accuracy

2024 data on employee disciplinary actions and regulatory inspections was restated/updated for accuracy in the 2025 report, with the number of regulatory inspections revised from 114 as originally reported.

▾ expand

CEO transition: Emma Walmsley succeeded by Luke Miels

Emma Walmsley stepped down as CEO and director on 31 December 2025 after leading an extensive transformation of GSK since 2017; Luke Miels, previously Chief Commercial Officer, became CEO effective 1 January 2026, following a multi-year structured succession process.

▾ expand

Agreement with US Administration to lower prescription medicine costs

GSK entered into an agreement with the US Government in December 2025 to lower the cost of prescription medicines for American patients, covering GSK and ViiV Healthcare, including a 3-year exclusion from Section 232 tariffs on pharmaceuticals manufactured in the UK.

▾ expand

Acquisition of IDRx, Inc.

GSK completed the acquisition of 100% of IDRx, Inc., a clinical-stage biopharmaceutical company developing precision therapeutics for gastrointestinal stromal tumours (GIST), including lead molecule IDRX-42 (now velzatinib), for upfront consideration of approximately £840 million plus contingent milestones.

▾ expand

Acquisition of BP Asset IX, Inc. (efimosfermin alfa)

GSK completed the acquisition of 100% of BP Asset IX, Inc., a subsidiary of Boston Pharmaceuticals providing access to efimosfermin alfa, a phase III-ready investigational medicine for steatotic liver disease, for upfront consideration of approximately £906 million plus contingent milestones.

▾ expand

see 23 more events →

2024

annual report ↗annual report ↗annual report ↗annual report ↗annual report ↗

Climate · carbon footprint (tCO2e)

Scope 1	521,000
Scope 2 (market-based)	44,000
Scope 3	8.4M
Cat 1 · Purchased goods	3.4M
Cat 9 · Downstream transport	358,000
Cat 11 · Use of sold products	4.7M
Cat 12 · End-of-life	89,500
Gross carbon footprint	9M
Net carbon footprint	9M

Energy (kWh)

Total energy	2.6B
Renewable electricity %	90%

Nature

water withdrawal m3	7Mm3
waste generated t	47,300tonnes

P&L highlights (USD)

Headcount (FTE)	68,629people
Revenue	31.4B
Cost of revenue	(9B)
Gross profit	22.3B
Operating expenses (S&M + G&A)	(18.3B)
Operating income	4B
Net income	2.6B

Balance sheet highlights (USD)

Property, plant & equipment	9.2B
Right-of-use (leased) assets	846M
Total assets	59.5B
Total debt	15.9B
Cash & equivalents	3.9B
Minority interest	-585M

Market & shares

Market cap (FY-end)	55.1B
Shares outstanding	2B

2023

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	581,000
Scope 2 (market-based)	64,000
Scope 3	9M
Cat 11 · Use of sold products	5M
Gross carbon footprint	9.6M
Net carbon footprint	9.6M

Energy (kWh)

Electricity	958M
Fuel (stationary + mobile)	1.6B
Heat / steam	39M
Total energy	2.6B
Renewable energy	(782M)
Non-renewable / hydrocarbon	1.9B
Renewable electricity %	83%

Nature

water withdrawal m3	7.4Mm3
water consumption m3	1.2Mm3
waste generated t	49,700tonnes
waste recycled t	26,200tonnes
waste hazardous t	18,300tonnes
waste landfill t	200tonnes
deforestation risk assessed pctⓘ	98%
biodiversity sites protected	9sites
water recycled pct	4%

Social

community investment amount	304MGBP
workforce female pct	48%
workforce management female pct	45%
ethnicity minority pct	21%
gender pay gap mean pct	-1%
employee turnover pct	6%
h s fatalities	0headcount
h s lost time injury rate	0per 100000 hours
h s total recordable injury rate	0per 100000 hours
supply chain audited pctⓘ	89%

Governance

workforce board female pct	42%
esg linked executive pay yn	1
audit assurance climate levelⓘ	1

Circularity

packaging recyclable pct	100%
recycled content input pct	86%

P&L highlights (USD)

Headcount (FTE)	70,212people
Revenue	30.3B
Cost of revenue	(8.6B)
Gross profit	21.8B
Operating expenses (S&M + G&A)	(15B)
Operating income	6.7B
Net income	4.9B

Balance sheet highlights (USD)

Property, plant & equipment	12.7B
Right-of-use (leased) assets	937M
Total assets	59B
Total debt	21.6B
Cash & equivalents	2.9B
Minority interest	-552M

Market & shares

Market cap (FY-end)	59.8B
Shares outstanding	2B

Events 2023· 78

Waste and materials reduction targets set for 2030

GSK targets a 25% environmental impact reduction for products and packaging by 2030, zero operational waste (including eliminating single-use plastics) by 2030, and a 10% waste reduction from its supply chain by 2030.

▾ expand

GSK aligns primarily to SDG3

GSK states its six ESG focus areas are aligned with the UN SDGs, and as a global biopharma company its most significant contribution is to SDG3: Good Health and Wellbeing.

▾ expand

GSK freshwater targets (stewardship, reduction, neutrality)

GSK targets: achieve good water stewardship at 100% of sites by 2025; reduce overall operational water use by 20% by 2030 (already achieved as of 2022, with a further 1% reduction in 2023, 24% cumulative reduction vs 2020 baseline); be water neutral in own operations and key suppliers in water-stressed regions by 2030; and achieve zero-impact API levels for all sites/key suppliers by 2030.

▾ expand

TNFD adoption and SBTN target validation commitment

GSK committed to adopting TNFD-aligned disclosures from 2026 (based on 2025 data) and was selected in 2023 to join the first group of companies in SBTN's initial target validation process, starting with freshwater and land targets.

▾ expand

SBTi approved GSK's 2045 net zero target

In 2023, the Science Based Targets initiative (SBTi) approved GSK's net zero target for 2045 in line with its Corporate Net-Zero Standard, covering 90% absolute emissions reduction from a 2020 baseline across all scopes plus neutralisation of residual emissions.

▾ expand

Waste and materials methodology changed to exclude on-site reuse

GSK changed its waste and materials methodology in 2023 to only include waste and materials leaving its sites, restating 2021 and 2022 waste and materials data to reflect this change.

▾ expand

GSK reports alignment primarily with SDG 3

GSK identifies its six ESG focus areas as aligned with the UN Sustainable Development Goals, stating that as a global biopharma company it can make the most significant contribution to SDG3: Good Health and Wellbeing.

▾ expand

Commitment to TNFD-aligned disclosures from 2026 (based on 2025 data)

GSK committed to adopting Taskforce on Nature-related Financial Disclosures (TNFD)-aligned disclosures in 2026, based on 2025 data, and began implementing final TNFD recommendations in its 2023 Annual Report disclosure.

▾ expand

Dependent: Supplier decarbonisation via Sustainable Procurement Programme

Goods and services purchased for manufacturing (Scope 3 supply chain) represent approximately 31% of GSK's total carbon footprint, which fell 2% in 2023. GSK's Sustainable Procurement Programme requires suppliers to act on climate and nature, with contract clauses on carbon reduction targeted at its top 30 suppliers by climate/nature impact; in 2023, 23% of these suppliers had submitted science-based targets for validation, with 8 approved. GSK collaborates industry-wide through the Activate and Energize programmes and the Sustainable Markets Initiative (SMI) Health Systems Task Force to reduce active pharmaceutical ingredient (API) production emissions.

▾ expand

Primary: Low-carbon Ventolin inhaler propellant transition (use of sold products)

Patient use of GSK's Ventolin (salbutamol) rescue metered-dose inhaler, prescribed to ~35 million people worldwide, accounts for just under half (48%) of GSK's total value-chain carbon footprint due to its propellant. GSK is investing in a low-carbon programme to transition to a next-generation, lower-carbon propellant with the potential to cut inhaler-related greenhouse gas emissions by 90%. Phase III trials begin in 2024, with regulatory submissions expected from 2025, supplementing GSK's existing low-carbon dry powder inhalers.

▾ expand

see 68 more events →

2022

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	626,418
Scope 2 (market-based)	88,368
Scope 3	9M
Cat 1 · Purchased goods	2.5M
Cat 2 · Capital goods	161,000
Cat 3 · Fuel + energy	145,000
Cat 4 · Upstream transport	242,000
Cat 5 · Waste in operations	51,000
Cat 6 · Business travel	85,000
Cat 7 · Employee commuting	60,000
Cat 8 · Upstream leased	0
Cat 9 · Downstream transport	130,000
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	5.5M
Cat 12 · End-of-life	47,000
Cat 15 · Investments	66,000
Gross carbon footprint	9.7M
Net carbon footprint	9.7M

Energy (kWh)

Electricity	970M
Fuel (stationary + mobile)	1.7B
Heat / steam	41M
Total energy	2.8B
Renewable energy	(697M)
Non-renewable / hydrocarbon	2.1B
Renewable electricity %	73%

Nature

water withdrawal m3	7.5Mm3
waste generated t	57,200tonnes
waste recycled t	22,500tonnes
waste hazardous t	26,100tonnes
waste landfill t	100tonnes
biodiversity sites protected	3sites
water consumption m3	1.6Mm3
water recycled pct	3%
deforestation risk assessed pctⓘ	90%

Social

community investment amount	308MGBP
workforce female pct	47%
employee turnover pct	7%
workforce board female pct	27%
h s lost time injury rate	0per 100000 hours
h s total recordable injury rate	0per 100000 hours
supply chain audited pctⓘ	82%
gender pay gap mean pct	-1%
workforce management female pct	50%
h s fatalities	0headcount
ethnicity minority pct	19%

Governance

esg linked executive pay yn	1
audit assurance climate levelⓘ	1

P&L highlights (USD)

Headcount (FTE)	90,422people
Revenue	29.3B
Cost of revenue	(9.6B)
Gross profit	19.8B
Operating expenses (S&M + G&A)	(13.3B)
Operating income	6.4B
Net income	15B

Balance sheet highlights (USD)

Property, plant & equipment	9.6B
Total assets	60.1B
Total debt	20B
Cash & equivalents	3.7B
Minority interest	-502M

Market & shares

Market cap (FY-end)	58.5B
Shares outstanding	2B

Events 2022· 67

New 2045 net-zero value chain target set

GSK set a new longer-term target to reduce carbon emissions by at least 90% by 2045 across all scopes, with the remainder tackled through high-quality offsets, aligned to the SBTi Net-Zero Standard definition of net zero. Submitted for SBTi verification in 2022.

▾ expand

Seeking SBTi re-accreditation as fully-focused biopharma company

Following the Haleon demerger, GSK is seeking re-accreditation from the SBTi for its carbon targets as a fully-focused biopharma company, reflecting the changed organisational boundary.

▾ expand

2030 water reduction target achieved ahead of schedule

GSK achieved its target of reducing overall water use in operations by 20% by 2030 against a 2020 baseline eight years early (23% reduction achieved by 2022), and will now review and likely tighten the target.

▾ expand

Waste metrics removed from Deloitte assurance scope due to data quality issues

Deloitte was unable to obtain sufficient evidence to support a conclusion on GSK's waste metrics due to data complexity; GSK undertook third-party remediation support and requested Deloitte remove waste metrics from the assurance engagement scope for 2022.

▾ expand

CDP ratings 2022: A- Climate, B Water, A- Forests (palm oil), B Forests (timber)

GSK received CDP scores of A- in Climate Change, B in Water Security, A- in Forests (palm oil) and B in Forests (timber) for 2022, reflecting mixed but generally strong disclosure performance across environmental themes.

▾ expand

TNFD membership adopted

GSK became a member of the Taskforce on Nature-related Financial Disclosures (TNFD), which is developing a risk management and financial disclosure framework similar to the TCFD.

▾ expand

Trialling Science Based Targets Network for Nature (SBTN) methodology

GSK is one of the first companies to trial the SBTN methodology to better understand its impacts and dependencies on nature, and completed a full assessment of biodiversity impact across the value chain in 2022.

▾ expand

Joined Race to Resilience campaign

GSK joined the Race to Resilience campaign in 2022, pledging to help 15 million people become more resilient to the health impacts of climate change by 2030, becoming the first biopharma company to join.

▾ expand

Sustainable Procurement Programme launched

GSK launched a Sustainable Procurement Programme in September 2022 requiring suppliers to act on carbon, power, heat, transport, water, waste and deforestation-free sourcing; from 2023 suppliers must disclose emissions and set 1.5C-aligned carbon reduction targets, extending climate accountability into the supply chain.

▾ expand

First global living wage review completed

GSK completed its first global living wage review in partnership with the Fair Wage Foundation, assessing pay for over 75,000 employees across 87 countries; adjustments identified in fewer than 200 cases across 11 countries to be completed by Q1 2023, with an annual review now built into standard cycle.

▾ expand

see 57 more events →

2021

sustainability report ↗

Climate · carbon footprint (tCO2e)

Scope 1	681,000
Scope 2 (market-based)	159,000
Scope 3	8.6M
Cat 1 · Purchased goods	2.7M
Cat 2 · Capital goods	154,000
Cat 3 · Fuel + energy	84,000
Cat 4 · Upstream transport	189,000
Cat 5 · Waste in operations	64,000
Cat 6 · Business travel	50,000
Cat 7 · Employee commuting	48,000
Cat 8 · Upstream leased	0
Cat 9 · Downstream transport	99,000
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	5.1M
Cat 12 · End-of-life	51,000
Cat 13 · Downstream leased	0
Cat 14 · Franchises	0
Cat 15 · Investments	41,000
Gross carbon footprint	9.5M
Net carbon footprint	9.5M

Energy (kWh)

Electricity	1.4B
Fuel (stationary + mobile)	1.8B
Heat / steam	93M
Total energy	3.6B
Renewable energy	(631M)
Non-renewable / hydrocarbon	3B
Renewable electricity %	67%

Nature

water withdrawal m3	10.2Mm3
water consumption m3	470,000m3
waste generated t	98,400tonnes
waste recycled t	42,200tonnes
waste hazardous t	34,200tonnes
waste landfill t	200tonnes
water recycled pct	4%
deforestation risk assessed pctⓘ	88%
biodiversity sites protected	3sites

Social

community investment amount	260.2MGBP
workforce female pct	47%
workforce management female pct	48%
ethnicity minority pct	20%
supply chain audited pctⓘ	80%
employee turnover pct	8%
h s lost time injury rate	0per 100000 hours
workforce board female pct	42%
h s total recordable injury rate	0per 100000 hours
gender pay gap mean pct	1%
h s fatalities	0headcount

Governance

audit assurance climate levelⓘ

P&L highlights (USD)

Headcount (FTE)	90,096people
Revenue	24.7B
Cost of revenue	(8.2B)
Gross profit	16.5B
Operating expenses (S&M + G&A)	(12.2B)
Operating income	4.4B
Net income	4.4B

Balance sheet highlights (USD)

Property, plant & equipment	14.5B
Total assets	107.1B
Total debt	31.6B
Cash & equivalents	5.8B
Minority interest	8.5B

Market & shares

Market cap (FY-end)	52.2B
Shares outstanding	1.6B

Events 2021· 64

Circular economy waste targets (zero operational waste by 2030)

In 2020 GSK changed the scope of its waste targets to support transition to a circular economy. New targets include zero operational waste (including eliminating single-use plastics) by 2030, 25% environmental impact reduction for products and packaging by 2030, and 10% waste reduction from the supply chain by 2030.

▾ expand

SBTi-validated 1.5C-aligned net zero targets across scopes 1,2,3

The Science Based Targets Initiative accredited GSK's carbon targets as aligned to a 1.5C pathway: net zero across operations (scope 1&2) by 2030, 100% renewable electricity by 2025, and net zero across the full value chain (scope 3) by 2030.

▾ expand

Net positive on nature by 2030 (TNFD, SBTN)

GSK set a target to be net positive on nature by 2030, reducing environmental impacts across water, materials and biodiversity. GSK is partnering with UNEP-WCMC to test the Science Based Targets for Nature (SBTN) methodology and is a member of the Taskforce on Nature-related Financial Disclosures (TNFD).

▾ expand

New water stewardship and neutrality targets

GSK set targets to achieve good water stewardship at 100% of sites by 2025, reduce overall water use in operations by 20% by 2030, be water neutral in own operations and at key suppliers in water-stressed regions by 2030, and achieve zero-impact API discharge levels by 2030. Joined the Water Resilience Coalition in 2021.

▾ expand

Net positive on nature by 2030; TNFD and SBTN engagement

GSK set a target to be net positive on nature by 2030 by reducing environmental impacts across water, materials and biodiversity. GSK is partnering with UNEP-WCMC to test the Science Based Targets for Nature (SBTN) methodology and is a member of the Taskforce on Nature-related Financial Disclosures (TNFD).

▾ expand

Contribution to UN SDGs, especially Goal 3

GSK's 13 Trust commitments contribute to many UN Sustainable Development Goals, with particular emphasis on Goal 3 (ensure healthy lives and promote wellbeing for all). Detailed SDG factsheet published separately on gsk.com.

▾ expand

Reframed 2030 climate target to comply with SBTi Net-Zero Standard

Following SBTi's 2021 publication of a new carbon Net-Zero Standard, GSK's 2030 target (previously stated as 'net zero by 2030') was reframed to explicitly state 80% carbon reductions across all scopes against a 2020 baseline plus 20% offset investment, improving definitional rigor and comparability.

▾ expand

Dependent: Supplier engagement and renewable electricity access in the supply chain

GSK partnered with Manufacture 2030 to proactively engage suppliers and measure/manage supply chain emissions reductions, and joined nine other global pharmaceutical companies to launch the Energize programme, using industry-scale power purchase agreements to expand renewable electricity access across pharmaceutical supply chains. Supplier Environmental Sustainability Awards recognise supplier progress.

▾ expand

Primary: Metered-dose inhaler propellant reformulation

Metered dose inhalers for asthma and COPD account for about 40% of GSK's carbon footprint because their propellant is a potent greenhouse gas (Scope 3 use-of-sold-products, ~5.3 million tCO2e in 2021). In 2021 GSK started an R&D programme to find a lower-impact propellant that could reduce emissions from its inhalers by about 90%.

▾ expand

Disciplinary data reporting methodology changed

In 2021, GSK changed the way it reports disciplinary data, expanding scope to include cases initiated in previous years but closed in 2021. Prior year data was restated using the new methodology for comparability, resulting in increases in some categories.

▾ expand

see 54 more events →

2020

annual report ↗

Climate · carbon footprint (tCO2e)

Scope 1	773,000
Scope 2 (market-based)	228,000
Scope 3	13.5M
Cat 1 · Purchased goods	5.6M
Cat 2 · Capital goods	226,000
Cat 3 · Fuel + energy	114,000
Cat 4 · Upstream transport	687,000
Cat 5 · Waste in operations	25,000
Cat 6 · Business travel	42,000
Cat 7 · Employee commuting	37,000
Cat 8 · Upstream leased	0
Cat 9 · Downstream transport	135,000
Cat 10 · Processing of sold	0
Cat 11 · Use of sold products	6.6M
Cat 12 · End-of-life	24,000
Cat 13 · Downstream leased	0
Cat 14 · Franchises	0
Cat 15 · Investments	41,000
Gross carbon footprint	14.5M
Net carbon footprint	14.5M

Energy (kWh)

Electricity	1.5B
Fuel (stationary + mobile)	1.9B
Heat / steam	80M
Total energy	3.9B
Renewable energy	(487M)
Non-renewable / hydrocarbon	3.4B
Renewable electricity %	52%

Nature

water withdrawal m3	12.5Mm3
water consumption m3	1.8Mm3
waste hazardous t	33,500tonnes
waste landfill t	2,200tonnes
water recycled pct	2%
waste generated t	108,100tonnes
waste recycled t	87,500tonnes

Social

workforce female pct	47%
workforce management female pct	48%
ethnicity minority pct	19%
employee turnover pct	6%
h s fatalities	3count
h s lost time injury rate	0per 100000 hours
h s total recordable injury rate	0per 100000 hours
supply chain audited pctⓘ	53%
workforce board female pct	42%
community investment amount	250MGBP

Governance

audit assurance climate levelⓘ

1level (0-2)

P&L highlights (USD)

Headcount (FTE)	94,066people
Revenue	34.1B
Cost of revenue	(7.9B)
Gross profit	26.2B
Operating expenses (S&M + G&A)	(10.4B)
Operating income	6B
Net income	5.7B

Balance sheet highlights (USD)

Property, plant & equipment	15B
Total assets	109.9B
Total debt	35.9B
Cash & equivalents	8.6B
Minority interest	8.5B

Market & shares

Market cap (FY-end)	53.6B
Shares outstanding	2B

Events 2020· 65

SDG alignment - primary contribution to Goal 3

GSK's 13 Trust commitments contribute to many UN Sustainable Development Goals; as a science-led global healthcare company, GSK states its biggest contribution is towards SDG 3: ensure healthy lives and promote well-being for all at all ages.

▾ expand

Renewable electricity via PPAs, RECs/REGOs and on-site generation

GSK sources purchased renewable electricity from suppliers under agreements evidenced by Renewable Energy Certificates (RECs), REGOs, or Power Purchase Agreements (PPAs), supplemented by on-site generation such as solar. Purchased renewable electricity surged to 750 GWh in 2020 (from ~51 GWh in 2019) plus 28 GWh generated on-site, lifting renewable electricity to 52% of total electricity used, up from 5% in each of the prior three years. GSK also recognises hydroelectric local grid supply (e.g. Quebec) as market-based low-carbon electricity for Scope 2 reporting.

▾ expand

High water risk site list updated (Xochimilco removed, Jamshoro added)

Following a 2020 review, the site in Xochimilco, Mexico was removed and the site in Jamshoro, Pakistan was added to GSK's list of high water risk sites; 2016 baseline data was restated to reflect this change.

▾ expand

Net zero climate impact target by 2030

GSK's Trust commitment on Environment states: 'Have a net zero impact on climate, and a net positive impact on nature by 2030.' Environmental targets use a 2016 baseline year.

▾ expand

2020 supplier quality audit figure corrected for duplication

2020 data for audits of third parties on quality processes was corrected from 1,839 to 1,451, as the original datapoint was mis-stated due to duplication of data from one part of the business; additional supplier audits were also identified that were not previously reported.

▾ expand

Full Scope 3 emissions total not available at 2020 report publication

Other than propellant emissions data (collected via internal systems), GSK states it will not have an accurate picture of Scope 3 GHG emissions for 2020 until later in the year; most Scope 3 category rows for 2020 are shown as unavailable ('-') in this report.

▾ expand

RE100 commitment: 100% renewable electricity by 2025

GSK is a member of RE100 and has committed to source 100% renewable electricity by 2025 (Scope 2). Renewable electricity share rose from 46% in 2020 to 73% in 2022 as a result.

▾ expand

Renewable electricity procurement via PPAs, RECs and REGOs

GSK defines purchased renewable electricity as electricity generated by a supplier and purchased under a supply agreement with evidence of origin such as RECs, REGOs, or as part of a Power Purchase Agreement (PPA). In 2020, purchased renewable electricity increased sharply from 51 GWh to 750 GWh, alongside 28 GWh of on-site generated renewable electricity, taking renewable electricity to 52% of total electricity used (up from 5% in 2019). Certificates of Origin may be retired after the reporting period, and GSK's assurance provider recommended assigning clearer organisational ownership for tracking renewable purchases across all sites.

▾ expand

Large jump in purchased renewable electricity (5% to 52% of electricity used)

GSK significantly increased the proportion of renewable electricity purchased from 5% in 2019 to 52% in 2020 (purchased renewable electricity rose from 51 GWh to 750 GWh). DNV's assurance report recommended improving the process for tracking which sites purchase renewable electricity and assigning clearer ownership of the tracking/evidence process.

▾ expand

2030 carbon ambition set: 80% reduction + 20% offset (2020 baseline)

In 2020, GSK set out a carbon ambition to achieve a net zero impact on climate by 2030, targeting 80% carbon reductions across all scopes against a 2020 baseline, with the remaining 20% offset through investment in high-quality nature-based solutions. This target was subsequently accredited by SBTi as aligned with a 1.5°C pathway.

▾ expand

see 55 more events →